Bohuta Lyubomyr, Chan Titus, Charette Kevin, Latham Gregory, Greene Christina L, Mauchley David, Koth Andrew, McMullan D Michael
Division of Cardiac Surgery, Seattle Children's Hospital, Seattle, Wash.
Division of Critical Care, Seattle Children's Hospital, Seattle, Wash.
JTCVS Open. 2024 Oct 11;22:450-457. doi: 10.1016/j.xjon.2024.10.006. eCollection 2024 Dec.
To evaluate the effect of a blood conservation program on trends in use of donor blood products and early clinical outcomes in infants undergoing open heart surgery.
Four hundred nine patients younger than age 1 year undergoing open-heart surgery between October 1, 2020, and June 30, 2023, were reviewed. The study period was divided into 4 eras with the first era as a before blood conservation baseline using traditional blood management. The following 3 eras comprised incremental implementation and evolution of blood conservation strategies. The total volume of blood products transfused for each surgical hospitalization was calculated and indexed to body weight at time of surgery.
There was no significant difference in age at surgery, body weight, distribution of The Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery categories, and in postoperative length of mechanical ventilation, intensive care unit or hospital length of stay, or postoperative mortality ( > .05 for all) across the 4 eras. Median total volume of blood products administered during hospitalization decreased from 128 mL/kg (range, 92-220 mL/kg) during the baseline period to 21 mL/kg (range, 6-44 mL/kg) during the last era ( < .01). Multivariate analysis demonstrated that later eras were associated with decreased odds of experiencing exposure to blood products during hospitalization.
Blood conservation is associated with significant reduction in usage of blood products during open heart surgery in infants with no significant effect on early outcomes. This trend is observed across all categories of surgical complexity. Additional studies are needed to prove consistency and to determine the longer-term clinical impact of this strategy.
评估血液保护方案对接受心脏直视手术的婴儿使用供血者血液制品趋势及早期临床结局的影响。
回顾了2020年10月1日至2023年6月30日期间409例年龄小于1岁接受心脏直视手术的患者。研究期分为4个阶段,第一个阶段为采用传统血液管理的血液保护基线期。接下来的3个阶段包括血液保护策略的逐步实施和演变。计算每次手术住院期间输注的血液制品总量,并根据手术时的体重进行指数化。
在4个阶段中,手术年龄、体重、胸外科医师协会-欧洲心胸外科协会分类分布、术后机械通气时间长度、重症监护病房或住院时间长度以及术后死亡率(所有均>0.05)均无显著差异。住院期间输注的血液制品总量中位数从基线期的128 mL/kg(范围92 - 220 mL/kg)降至最后一个阶段的21 mL/kg(范围6 - 44 mL/kg)(<0.01)。多变量分析表明,后期阶段与住院期间接触血液制品的几率降低相关。
血液保护与婴儿心脏直视手术期间血液制品使用量的显著减少相关,对早期结局无显著影响。在所有手术复杂性类别中均观察到这一趋势。需要进一步研究以证明其一致性,并确定该策略的长期临床影响。